STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Public ClinicalTrials.gov record NCT06960213. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Study identification
- NCT ID
- NCT06960213
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- ADARx Pharmaceuticals, Inc.
- Industry
- Enrollment
- 90 participants
Conditions and interventions
Interventions
- ADX-324 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 27, 2025
- Primary completion
- Jun 29, 2027
- Completion
- Dec 30, 2027
- Last update posted
- Apr 21, 2026
2025 – 2027
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ADARx Clinical Site | Litchfield Park | Arizona | 85340 | Recruiting |
| ADARx Clinical Site | Little Rock | Arkansas | 72205 | Recruiting |
| ADARx Clinical Site | San Diego | California | 92122 | Recruiting |
| ADARx Clinical Site | Walnut Creek | California | 94598 | Recruiting |
| ADARx Clinical Site | Orlando | Florida | 32807 | Recruiting |
| ADARx Clinical Site | Chevy Chase | Maryland | 20815 | Recruiting |
| ADARx Clinical Site | Wheaton | Maryland | 20902 | Recruiting |
| ADARx Clinical Site | Detroit | Michigan | 48202 | Recruiting |
| ADARx Clinical Site | St Louis | Missouri | 63141 | Recruiting |
| ADARx Clinical Site | Las Vegas | Nevada | 89128 | Recruiting |
| ADARx Clinical Site | New York | New York | 10029 | Recruiting |
| ADARx Clinical Site | Cincinnati | Ohio | 45236 | Recruiting |
| ADARx Clinical Site | Columbus | Ohio | 43235 | Recruiting |
| ADARx Clinical Site | Toledo | Ohio | 43617 | Recruiting |
| ADARx Clinical Site | Hershey | Pennsylvania | 17033 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06960213, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2026 · Synced Apr 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06960213 live on ClinicalTrials.gov.